Leflunomide and Metastatic neoplasm - a phase IV clinical study of FDA data

Summary:

Metastatic neoplasm is reported as a side effect among people who take Leflunomide (leflunomide), especially for people who are female, 60+ old, also take Prednisolone, and have Neuroendocrine carcinoma of the skin.

The phase IV clinical study analyzes which people have Metastatic neoplasm when taking Leflunomide. It is created by eHealthMe based on reports of 81,713 people who have side effects when taking Leflunomide from the FDA, and is updated regularly.

What is Leflunomide?

Leflunomide has active ingredients of leflunomide. It is often used in rheumatoid arthritis. eHealthMe is studying from 82,105 Leflunomide users. Check the latest studies of Leflunomide.

What is Metastatic neoplasm?

Metastatic neoplasm (spreadable cancer tumour) is found to be associated with 602 drugs and 516 conditions by eHealthMe. Check the latest studies of Metastatic neoplasm.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 17, 2026

81,713 people reported to have side effects when taking Leflunomide.
Among them, 15 people (0.02%) have Metastatic neoplasm.

Could Leflunomide cause Metastatic neoplasm?

Among these 15 people:

What is the gender of people who have Metastatic neoplasm when taking Leflunomide? *

female: 57.14 %
male: 42.86 %

What is the age of people who have Metastatic neoplasm when taking Leflunomide? *

What are other drugs people take besides Leflunomide? *

What are other side effects people have besides Metastatic neoplasm? *

Neuroendocrine Carcinoma Of The Skin (a rare type of cancer that forms on or just beneath the skin, usually in parts of the body that have been exposed to the sun): 6 people, 40.00%
Pneumonia: 3 people, 20.00%
Tuberculosis (a bacterial infection by mycobacterium tuberculosis): 1 person, 6.67%
Leukopenia (less number of white blood cells in blood): 1 person, 6.67%
Brain Neoplasm Malignant (brain cancer tumour): 1 person, 6.67%
Cardiac Failure: 1 person, 6.67%
Chronic Obstructive Pulmonary Disease (a progressive disease that makes it hard to breathe): 1 person, 6.67%
Cytomegalovirus Infection: 1 person, 6.67%
Death: 1 person, 6.67%
Drug Ineffective: 1 person, 6.67%

What are the existing conditions these people have? *

Neuroendocrine Carcinoma Of The Skin (a rare type of cancer that forms on or just beneath the skin, usually in parts of the body that have been exposed to the sun): 1 person, 6.67%

* Approximation only. Some reports may have incomplete information.

Do you take Leflunomide and have Metastatic neoplasm?

- Check whether Metastatic neoplasm is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Leflunomide:

Leflunomide (82,105 reports)

Browse all side effects of Leflunomide:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Metastatic neoplasm:

Metastatic neoplasm (602 drugs)

Browse all the conditions that are associated with Metastatic neoplasm:

Metastatic neoplasm (516 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on leflunomide (the active ingredients of Leflunomide) and Leflunomide (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.